The United States Patent and Trademark Office (USPTO) has published the trademark application for 'KIZELMY' (TM79437892) for opposition. The application, filed on October 16, 2025, seeks to register the mark for a range of pharmaceutical products, including monoclonal antibodies and preparations for the treatment of arthritis, spondylitis, psoriasis, and autoimmune diseases.

This publication initiates a period during which any party who believes they would be harmed by the registration of this mark can file an opposition. Companies operating in the pharmaceutical sector, particularly those dealing with similar product categories or branding, should monitor this proceeding if they have potential grounds for opposition. The opposition period is critical for preventing potential trademark infringement or confusion in the marketplace.